Besides the potential for bone loss, as well as the possibility that there may be “resistance” to the metabolic effects of elevated FGF21 in T2D7, further elevation in FGF21’s systemic activity may exacerbate the development of diabetic cardiomyopathy and other conditions characterized by concentric cardiac hypertrophy. This evidence concerns the gene FGF21 and diabetic cardiomyopathy.